Please use this identifier to cite or link to this item:
https://ir.swu.ac.th/jspui/handle/123456789/14064
Title: | Enhancement of lymphangiogenesis in vitro via the regulations of HIF-1 α expression and nuclear translocation by deoxyshikonin |
Authors: | Prangsaengtong O. Park J.Y. Inujima A. Igarashi Y. Shibahara N. Koizumi K. |
Keywords: | deoxyshikonin hypoxia inducible factor 1alpha messenger RNA shikonin derivative unclassified drug vasculotropin C article cell function controlled study drug mechanism endothelium cell gene expression regulation gene silencing gene translocation genetic transfection human human cell in vitro study lymphangiogenesis priority journal protein expression |
Issue Date: | 2013 |
Abstract: | The objectives of this study were to determine the effects of deoxyshikonin on lymphangiogenesis. Deoxyshikonin enhanced the ability of human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) to undergo time-dependent in vitro cord formation. Interestingly, an opposite result was observed in cells treated with shikonin. The increased cord formation ability following deoxyshikonin treatment correlated with increased VEGF-C mRNA expression to higher levels than seen for VEGF-A and VEGF-D mRNA expression. We also found that deoxyshikonin regulated cord formation of HMVEC-dLy by increasing the HIF-1α mRNA level, HIF-1α protein level, and the accumulation of HIF-1α in the nucleus. Knockdown of the HIF-1α gene by transfection with siHIF-1α decreased VEGF-C mRNA expression and cord formation ability in HMVEC-dLy. Deoxyshikonin treatment could not recover VEGF-C mRNA expression and cord formation ability in HIF-1α knockdown cells. This indicated that deoxyshikonin induction of VEGF-C mRNA expression and cord formation in HMVEC-dLy on Matrigel occurred mainly via HIF-1α regulation. We also found that deoxyshikonin promoted wound healing in vitro by the induction of HMVEC-dLy migration into the wound gap. This study describes a new effect of deoxyshikonin, namely, the promotion of cord formation by human endothelial cells via the regulation of HIF-1α. The findings suggest that deoxyshikonin may be a new drug candidate for wound healing and treatment of lymphatic diseases. © 2013 Orawin Prangsaengtong et al. |
URI: | https://ir.swu.ac.th/jspui/handle/123456789/14064 https://www.scopus.com/inward/record.uri?eid=2-s2.0-84877964031&doi=10.1155%2f2013%2f148297&partnerID=40&md5=d06d5e7699423d7a8aa64b5e2a799cdc |
ISSN: | 1741427X |
Appears in Collections: | Scopus 1983-2021 |
Files in This Item:
There are no files associated with this item.
Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.